Sobi Announces Optimistic Full-Year Projection and Early Q3 Financial Report Release

Sobi's Revised Outlook for 2025

Swedish Orphan Biovitrum AB (Sobi) has publicly announced an updated financial outlook for the year 2025, showcasing a revised revenue projection that reflects ongoing advancements and performance improvements within the company. In light of recent developments, Sobi now expects revenue growth to be in the low double-digit percentage range when measured at constant exchange rates, up from the previous estimate of a high single-digit percentage growth.

The company is set to release its third-quarter financial report on October 20, 2025, ahead of the previously scheduled date, signifying its commitment to transparency regarding its financial status and operational performance. This timely update allows stakeholders and investors to better understand Sobi's trajectory in what has proven to be a dynamic marketplace.

In the third quarter of 2025, Sobi reported substantial revenue of SEK 7,776 million, representing a remarkable 21 percent growth compared to the same quarter in the previous year, adjusted for constant exchange rates. This increase is attributed to the strong performance of products such as Altuvoct, Doptelet, and Gamifant. Such robust sales underscore the company's strategic focus on enhancing the market presence of its innovative therapies aimed at rare diseases.

Continued Financial Performance Improvement

The firm also reported an impressive adjusted EBITA margin of 47 percent for Q3 2025, significantly benefiting from disciplined cost management and a reduction in research and development expenditures. The greater efficiency has emerged from strategic organizational changes initiated earlier in 2025, and this has positioned Sobi favorably in achieving its financial goals. Year-to-date revenue has reached SEK 20,417 million, a 15 percent increase when compared to the same period last year at constant exchange rates. The adjustment in EBITA forecasts reflects a proactive approach to anticipated market scenarios.

Furthermore, Sobi has recorded a non-cash impairment charge of SEK 6,612 million related to the product and marketing rights for Vonjo. Despite this setback, the firm maintains confidence in Vonjo's potential as a crucial long-term growth engine. Positive developments are expected following regulatory advances, including an anticipated FDA review of the NASP biologics license application slated for mid-2026.

New Market Opportunities on the Horizon

In addition to its financial updates, Sobi recently received approval for its Tryngolza (olezarsen) product targeting familial chylomicronaemia syndrome (FCS) in Europe. There is a projected market potential exceeding SEK 5 billion within major European markets, including France, Germany, Italy, and Spain due to the significant prevalence of multifactorial chylomicronemia syndromes, which could lead to further market growth opportunities.

Sobi’s commitment to innovation doesn’t stop here; the company is also preparing for further regulatory filings in Europe concerning other conditions associated with severe hypertriglyceridemia, enhancing its portfolio in rare disease treatments.

Conclusion

In summary, Sobi's current initiatives position it strongly within the biopharmaceutical landscape, leveraging financial advancements and product approvals that cater to pressing healthcare needs. Stakeholders are encouraged to stay informed through the upcoming financial reporting and conference call, scheduled for the same day as the Q3 report release. Sobi's growth narrative is one of resilience, informed strategy, and a dedicated focus on empowering those battling rare diseases.

For more information about Sobi’s innovative solutions and financial updates, stakeholders can follow the conference call live or access subsequent recordings on the company's official website.